WO2004020407A1 - ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩 - Google Patents

４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩 Download PDF

Info

Publication number
WO2004020407A1
WO2004020407A1 PCT/JP2003/010828 JP0310828W WO2004020407A1 WO 2004020407 A1 WO2004020407 A1 WO 2004020407A1 JP 0310828 W JP0310828 W JP 0310828W WO 2004020407 A1 WO2004020407 A1 WO 2004020407A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
compound
benzenesulfonate
hydroxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/010828
Other languages
English (en)
French (fr)
Inventor
Hiroshi Fukushima
Akira Hiratate
Masato Takahashi
Kazuya Kameo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004532725A priority Critical patent/JP3746063B2/ja
Priority to HK06102523.6A priority patent/HK1082497B/xx
Priority to NZ538956A priority patent/NZ538956A/en
Priority to UAA200502704A priority patent/UA78104C2/uk
Priority to BR0313831-3A priority patent/BR0313831A/pt
Priority to US10/525,748 priority patent/US7304166B2/en
Priority to CA002496623A priority patent/CA2496623C/en
Priority to MXPA05002253A priority patent/MXPA05002253A/es
Priority to EA200500420A priority patent/EA007613B1/ru
Priority to EP03791325A priority patent/EP1535907A4/en
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to AU2003261748A priority patent/AU2003261748B2/en
Priority to HR20050205A priority patent/HRP20050205A2/hr
Publication of WO2004020407A1 publication Critical patent/WO2004020407A1/ja
Priority to NO20050867A priority patent/NO20050867L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to a 4-fluoro-2-cyanopyrrolidine derivative benzenesulfonate.
  • Dipeptidyl peptidase IV is a serine protease and is widely distributed in tissues such as kidney and liver and in plasma, and is involved in the metabolism of various bioactive peptides.
  • the present invention provides a 4-fluoro-12-cyanopyrrolidine derivative exhibiting excellent DPPIV inhibitory activity and having properties required for a drug such as stability. Disclosure of the invention
  • the present inventors have conducted various studies on the 4-fluoro-2-cyanopyrrolidine derivative in order to achieve the above object, and as a result, have found that a preferred stable compound can be obtained by forming a salt of benzenesulfonic acid. Completed the invention.
  • the present invention provides a compound of the formula [I]
  • the benzenesulfonate of the present invention can be obtained by the method described in WO02 / 38541, (2S, 4S) -2-cyano-14-fluoro-1-([2-hydroxy-11,1-dimethyl) ethylamino] a Dissolve cetylpyrrolidine in an appropriate solvent, mix benzenesulfonic acid or its hydrate directly or in a dissolved state, and filter the resulting precipitate or the precipitate obtained by adding a poor solvent as the intended product Is obtained by
  • the compound of the present invention has excellent crystallinity, and is easily obtained as a uniform crystal form as compared with other salt compounds (for example, tosylate).
  • a more stable composition could be produced with respect to the stability when mixed with a compounding agent usually used in the manufacture of pharmaceuticals.
  • the compound of the present invention can inhibit dipeptidyl peptidase IV in vivo, thereby enhancing insulin action and improving glucose metabolism, and inhibiting the metabolism of neuropeptide Y, T It can contribute to suppressing cell activation, suppressing adhesion of cancer cells to endothelium, and preventing HIV virus from entering lymphocytes.
  • the present invention provides a disease or condition that can be improved by inhibiting dipeptidyl peptidase IV, for example, diabetes (particularly type 2), immune disease, arthritis, obesity, osteoporosis, glucose tolerance damage, The above physician for preventing or treating benign prostatic hypertrophy, skin disease, etc. Provide medicine.
  • compositions for immune diseases include immunosuppressants in tissue transplantation; for example, cytoin release inhibitors in various autoimmune diseases such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis (RA), Agents useful for the prevention and treatment of AIDS by preventing HIV entry into T-cells, including those that prevent metastasis, especially those that prevent breast and prostate tumors from metastasizing to the lungs.
  • the medicament of the present invention can be systemically or locally administered orally or parenterally, such as intrarectally, subcutaneously, intramuscularly, intravenously, transdermally, and the like.
  • a solid composition, a liquid composition, and any other form of a composition may be used, and the most suitable one may be selected as needed.
  • the medicament of the present invention can be produced by blending a pharmaceutically acceptable carrier with the compound of the present invention. Specifically, conventional excipients, extenders, binders, disintegrants, coatings, sugar coatings, H adjusters, solubilizers, or aqueous or non-aqueous solvents are added, and then used in conventional formulation techniques. , Tablets, pills, capsules, granules, powders, powders, solutions, emulsions, suspensions, injections, and the like.
  • the compound of the present invention can be formulated by forming an inclusion compound with ⁇ - or ⁇ -cyclodextrin or methylated cyclodextrin.
  • the dose of the compound of the present invention varies depending on the disease, symptom, body weight, age, sex, administration route and the like.For an adult, oral administration is preferably about 1 to about 1.000 mg / person / day, More preferably, the dose is about 10 to about 200 mg I person / day, which can be administered once or several times a day.
  • (2S, 4S) _ 2-cyano 4-fluoro-11-[(2-hydroxy-1-1,1-dimethyl) ethylamino] acetylpyrrolidine (20 g) was heated and dissolved in methanol (300 mL), and benzenesulfonic acid in water When a solution of the hydrate (15.2 g) in methanol (30 mL) was added, powder precipitated. After adding diisopropyl ether (330 mL) to the suspension, the powder was collected by filtration to obtain a colorless powder of the title compound (31.5 g).
  • Test example 1 [Weight change test under humidification]
  • Each sample lO.Omg was weighed into a microtube (diameter 8 mm, length 50 mm) and left in a desiccator filled with water so as not to come in contact with water.
  • the desiccator was left at room temperature. The state was observed and the weight was measured over time, and the weight change was expressed as a percentage.
  • the residual ratio was measured in the following procedure. 10 ml of the HPLC mobile phase was added to the test tube after a predetermined storage period, dissolved and quantified by HPLC, and the area was compared with the initial value before heating or before heating and humidification to calculate the residual ratio of the drug.
  • UV absorption spectrophotometer Detection wavelength: 210nm
  • Formulation A drug 10 mg, crystalline cellulose 68 mg, magnesium stearate 2 mg
  • Formula B drug 10 mg, lactose 68 mg, hydrogenated oil 2 mg
  • the mixture was mixed for 1 hour with a mix rotor (MIX-ROTAR VMR-5, Seiko Inoue).
  • MIX-ROTAR VMR-5 Seiko Inoue
  • Formulation B was mixed with 16 ⁇ l of purified water and stirred with an E, 'Lutex mixer (TOUCH MIXER MT-31, Yamato Scientific). This was stored at 65 ° C for 1 week in a sealed, completely protected from light, the content after storage was measured, and the residual ratio was calculated.
  • the content was determined by the procedure described below. After adding 10 ml of 50% methanol to the sample after storage, irradiate it with ultrasonic waves (using BRANSONIC 5200 from BRANSON) for 30 minutes for dispersion and extraction, and shake for 1 hour with a shaker. Was transferred to a 50 ml volumetric flask. The female was washed with 50% methanol. This was further irradiated with ultrasonic waves for 30 minutes. This solution was filtered through a 0.45 m membrane run filter, fractionated into 5 mi, and quantified by HPLC using a 50 ml methanol solution in a 10 ml volumetric flask as a sample solution. HPLC conditions were the same as in Test Example 2. is there.
  • Example 1 showed little deterioration even when a compounding agent used in manufacturing a pharmaceutical was added, and could provide a compounded composition stable as a pharmaceutical.
  • the compound of the present invention is easily obtained as a highly pure and uniform crystal form, and has excellent stability under high humidity conditions. Therefore, the adhesion of powder to the machine and the decrease in fluidity during manufacturing are eliminated, and the stable supply of pharmaceuticals containing the present compound is enabled. In addition, since this compound is also excellent in solid stability, it has no problems with changes in appearance, transition of crystal form, etc., withstands severe conditions during production as a pharmaceutical, It also enables long-term quality maintenance when added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

優れたDPPIV阻害活性を示し、且つ安定性等の医薬品として必要な物性を兼ね備えた（２Ｓ,４Ｓ）−２−シアノ-−４−フルオロ−[（２−ヒドロキシ−１,１−ジメチル）エチルアミノ]アセチルピロリジン・ベンゼンスルホン酸塩。本発明は高純度且つ均一な結晶系としての取得が容易であり、優れた固体安定性を備えている。

Description

明細書
4一フルォロ一 2—シァノピロリジン誘導体ベンゼンスルホン酸塩 技術分野
本発明は、 4_フルオロー 2 _シァノピロリジン誘導体ベンゼンスルホン酸塩に関す る。 背景技術
ジぺプチジルぺプチダーゼ IV (DPPIV)はセリンプロテアーゼの一種であり、腎臓、肝 臓など広く組織、血漿中に分布しており、さまざまな生理活性ペプチドの代謝に関与し ている。
DPPIV 阻害化合物としては、（2S, 4S) _ 2—シァノ一4—フルオロー 1 _ [ (2—ヒドロ キシー 1 , 1—ジメチル）ェチルァミノ]ァセチルピロリジン (WO02/38541)が知られて いる。しかし遊離体は固体安定性が悪く、該出願で示されている鉱酸との塩及び有機 酸との塩化合物は、固体安定性、加湿下での安定性が悪 また合成上の困難性を有 する等の欠点があった。
本発明は、優れた DPPIV阻害活性を示し、且つ安定性等の医薬品として必要な物性 を兼ね備えた 4—フルォロ一2—シァノピロリジン誘導体を提供する。 発明の開示
本発明者らは、上記目的を達成するべく 4一フルオロー 2—シァノピロリジン誘導体に 関して種々検討した結果、ベンゼンスルホン酸の塩にすることで好ましい安定な化合物 が得られることを見いだし、本発明を完成した。
すなわち本発明は、式 [I]
Figure imgf000003_0001
で表される（2S， 4S)— 2—シァノ一4—フルォロ一 1— [ (2—ヒドロキシ一 1, 1一ジメチ ノレ）ェチルァミノ]ァセチルピロリジン ·ベンゼンスルホン酸塩である。 発明を実施するための最良の形態
本発明のベンゼンスルホン酸塩は、 WO02/38541 記載の方法により得られる（2S, 4 S) - 2-シァノ一 4一フルォロ一 1— [ ( 2—ヒドロキシ一 1 , 1 -ジメチル）ェチルァミノ]ァ セチルピロリジンを適当な溶媒に溶解し、ベンゼンスルホン酸またはその水和物を直接 または溶解した状態で混合し、その後の析出物または貧溶媒を添加した際の析出物を 目的物として濾取することにより得られる。本発明化合物は上記方法により、結晶性も優 れ、他の塩化合物（例えばトシル酸塩）に比べ、均一な結晶形としての取得が容易であ る。また、通常医薬品製造時に用いる配合剤と混合した際の安定性についても、より安 定した組成物が製造できた。
本発明化合物は、生体内でジぺプチジルぺプチダーゼ IVを抑制することができ、よつ て、インスリン作用を亢進し糖代謝を改善することができ、また、ニューロペプチド Yの代 謝抑制、 T細胞の活性化抑制、癌細胞の内皮への接着抑制、 HIVウィルスのリンパ球へ の進入防止に寄与することができる。
したがって、本発明は、ジぺプチジルぺプチダーゼ IVを阻害することで改善しうる疾患 又は状態、例えば、糖尿病（特に 2型）、免疫疾患、関節炎、肥満、骨粗しょう症、耐糖 性損傷の状態、良性の前立腺肥大、皮膚病などを予防または治療するための上記医 薬を提供する。
免疫疾患のための医薬としては、組織移植における免疫抑制剤；例えば、炎症腸病、 多発硬化症、慢性関節リウマチ (RA)の様な様々な自己免疫症でのサイト力イン放出抑 制剤、 T—細胞への HIVの侵入防止による、 AIDSの-予防及ぴ治療に有用な薬剤、転 移防止、特に乳及び前立腺腫瘍の肺への転移を防止する薬剤などがあげられる。 本発明の医薬は、全身的又は局所的に経口又は直腸内、皮下、筋肉内、静脈内、経 皮等の非経口投与することができる。
本発明の化合物を医薬として用いるためには、固体組成物、液体組成物、及びその 他の組成物のいずれの形態でもよぐ必要に応じて最適のものが選択される。本発明の 医薬は、本発明の化合物に薬学的に許容されるキヤリヤーを配合して製造することがで きる。具体的には、常用の賦形剤、増量剤、結合剤、崩壊剤、被覆剤、糖衣剤、 H 調 整剤、溶解剤、又は水性若しくは非水性溶媒などを添加し、常用の製剤技術によって、 錠剤、丸剤、カプセル剤、顆粒剤、粉剤、散剤、液剤、乳剤、懸濁剤、注射剤、などに調 製する事ができる。
また、本発明化合物は、ひ、 若しくは γ—シクロデキストリン又はメチル化シクロデキ ストリン等と包接化合物を形成させて製剤化することができる。
本発明化合物の投与量は、疾患、症状、体重、年齢、性別、投与経路等により異なる 力 S、成人に対し、経口投与の場合、好ましくは約 1〜約 1.000 mg /人/日であり、より好 ましくは約 10〜約 200 mg I人/日であり、これを 1日 1回又は数回に分けて投与するこ とができる。
さらに参考例、実施例、試験例により本発明を説明する。 参考例 1
(2S, 4S)—2—シァノー 4—フノレオ口一 1— [ (2—ヒドロキシ一 1 , 1 ージメチル）ェチル ァミノ]ァセチルピロリジン ·塩酸塩の合成
(2S, 4S)— 2—シァノ一4—フルオロー 1ー[ (2—ヒドロキシ一 1, 1—ジメチル）ェチル ァミノ]ァセチルピロリジン (5.00g)のメタノール (75mL)懸濁液に、 4M塩酸（酢酸ェチル溶 液、 6.17mL)を加えると透明な溶液になった。この溶液にジイソプロピルエーテル (300mL)を加えて攪拌し、析出した粉末を濾取して、無色粉末の表題化合物（5.47g)を 得た。
融点： 197- 198°C
参考例 2
(2S, 4S)— 2—シァノ一 4一フルオロー 1 _[ (2—ヒドロキシ一 1, 1ージメチル）ェチノレア ミノ]ァセチルピロリジン'メタンスルホン酸塩の合成
(2S， 4S)— 2—シァノー 4—フルオロー 1— [ (2—ヒドロキシ一 1 , 1—ジメチル）ェチル ァミノ]ァセチルピロリジン (0.15g)のメタノール (0.92mL)懸濁液に、メタンスルホン酸 (0.042mL)のメタノール (0.08mL)溶液を加えると透明な溶液になった。この溶液を、ジイソ プロピルエーテル (5mL)に攪拌しながら滴下した。析出した粉末を濾取して、無色粉末 の表題化合物 (0.20g)を得た。
融点： 179- 180°C 実施例 1
(2S, 4S)— 2—シァノ一4一フルオロー 1一 [(2—ヒドロキシー 1， 1—ジメチル）ェチルァ ミノ]ァセチルピロリジン ·ベンゼンスルホン酸塩の合成
(1) (2S, 4S)— 2—シァノー 4_フルオロー 1— [ (2—ヒドロキシー 1， 1ージメチル）ェチ ルァミノ]ァセチルピロリジン
2—ァミノ一 2—メチル一 1 _プロパノール（0.54g)をテトラヒドロフラン（7.5mL)とェタノ ール (2.5ml)の混合溶媒に溶解し、水冷下（2S， 4S)—1—ブロモアセチルー 2—シァノ — 4一フルォロピロリジン (0.71g)を加え、室温で 1時間攪拌した。析出した結晶を濾取し、 無色固体として表題化合物 (0.36g)を得た。更に濾液をシリカゲルカラムクロマトグラフィ (展開溶媒；クロ口ホルム：メタノール： 25%アンモニア水 = 300 : 10 : 1)で精製し、表題 化合物 (0.22g)を得た。
(2) (2S, 4S)— 2—シァノ一4—フルオロー 1— [ (2—ヒドロキシー 1, 1—ジメチル）ェチ ルァミノ]ァセチルピロリジン'ベンゼンスルホン酸塩 (2S, 4S) _ 2—シァノー 4—フルオロー 1一 [(2—ヒドロキシ一 1， 1ージメチル）ェチル ァミノ]ァセチルピロリジン (20g)をメタノール (300mL)に加温溶解し、ベンゼンスルホン酸 1 水和物 (15.2g)のメタノール (30mL)溶液を加えたところ粉末が析出した。この懸濁液にジ イソプロピルエーテル (330mL)を加えた後、粉末を濾取して無色粉末の表題化合物 (31.5g)を得た。
融点： 220- 221°C
試験例 1 [加湿下での重量変化試験]
各検体 lO.Omgをミクロチューブ（直径 8mm、長さ 50mm)にはかりとり、水をはったデシ ケータの中に水に接しないように放置した。デシケータは、室温に放置した。経時的に 状態観察と重量測定を行い、重量変化を百分率表示した。
ぐ重量変化と状態変化 >
【表 1】
Figure imgf000006_0001
参考例 1の塩酸塩と参考例 2のメタンスルホン酸塩は吸湿して潮解した力 実施例 1の ぐノゼンスルホン酸塩は重量変化せず潮解しなかった。 試験例 2 [固体安定性試験]
各検体約 lmg を精密に量り取り、加温条件（70°C)では遮光（アルミ箔)密栓、加温 ·加 湿条件（40°C'75%RH)では遮光（アルミ箔）開栓のネジロ試験管に入れ保存した。薬物の 2003/010828
6 残存率測定は以下の手順で行った。所定の保存期間が終了した試験管に HPLC移動 相 10mlを加えて溶解後 HPLCで定量し、これを加温又は加温'加湿前の初期値と面積 比較して薬物の残存率を算出した。
*HPLC条件
カラム： CAPCELL PAK UG120, 5 μ πι, φ 4.6 X 150mm (SHISEIDO) '
カラム温度： 40°C
検出：紫外吸光光度計 (検出波長： 210nm)
流速： l .Oml/min
注入量： ΙΟ μ Ι
移動相：水/ァセトニトリル/リン酸/ SDS (700:300: 1 :2)
く薬物の残存率 >
【表 2】
Figure imgf000007_0001
参考例 1の塩酸塩と参考例 2のメタンスルホン酸塩は、何れの条件でも薬物の残存率 が 97%以下であつたが、実施例 1のベンゼンスルホン酸塩は何れの条件でも 99 %以上 であった。 試験例 3 [添加剤との配合変化試験]
Serajuddin A.T.M.らの報告（J.Pharm.Sci., 88,696-704, 1999)に準じて行った。配合 A (原薬 10mg、結晶セルロース 68mg、ステアリン酸マグネシウム 2mg)又は配合 B (原薬 10mg、乳糖 68mg、硬化油 2mg)の分量で、原薬と添加剤をねじ口試験管中に枰量後、 ミックスロ-タ- (MIX- ROTAR VMR-5、井内盛栄堂）で 1時間混合した。配合 Aには何も添 加せず、配合 Bには精製水 16 μ ΐを添カ卩し、ホ、'ルテックスミキサー (TOUCH MIXER MT- 31、 ャマト科学)で攪拌した。これを密栓'完全遮光状態で 65°C ' l週間保存して、保存後の 含量を測定し、残存率を算出した。
含量は次に記す手順により求めた。保存後の試料に 50%メタノ ル 10mlを加え、分散お よび抽出のために超音波（BRANSON 社の BRANSONIC 5200を使用）を 30分間照射 した後、振とう機で 1時間振とうし、この液を 50mlメスフラスコに移した。 50%メタノ-ルで洗い込 みメスアツズを行なった。ここに更に超音波を 30分間照射した。本液を 0.45 mメンフ "ランフ ィルターでろ過後 5mi分取し、 10mlのメスフラスコに 50%メタノールでメスアツフ。したものを試料溶液 とし、 HPLCで定量した。 HPLC条件は試験例 2と同様である。
<薬物の残存率〉
Figure imgf000008_0001
配合 Aの場合、参考例 2のメタンスルホン酸塩では、薬物の残存率は 91.6%になってし まうが、実施例 1のベンゼンスルホン酸塩ではほとんどその低下はみられなかった。また、 メタンスルホン酸塩の残存率が 74.5%に低下してしまう配合 Bの場合でも、ベンゼンスル ホン酸塩は 90%以上の残存率を示した。
実施例 1の化合物は、医薬品製造時に用いる配合剤を加えても劣化が少なく、医薬品 として安定した配合組成物を提供できることが確認された。 産業上の利用可能性
本発明化合物は、高純度で均一な結晶形として取得が容易であり、高湿度条件下に おいて優れた安定性を備えている。したがって、製造時における機械への粉体の付着、 流動性の低下等が解消され、本化合物を含む医薬品の安定的供給を可能とする。また 本化合物は、固体安定性にも優れていることから、外観の変化、結晶形の転移等につ いての問題はなく、医薬品としての製造時における過酷な条件下にも耐え、配合剤添 加時の長期品質保持をも可能とする。

Claims

請求の範囲
ァノ一 4—フルオロー 1— [ (2—ヒドロキシ一1, 1—ジメチル）ェチ ί π、、 ソ ·ベンゼンスノレホン酸塩。
PCT/JP2003/010828 2002-08-29 2003-08-27 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩 Ceased WO2004020407A1 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA200500420A EA007613B1 (ru) 2002-08-29 2003-08-27 Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
NZ538956A NZ538956A (en) 2002-08-29 2003-08-27 Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivative used to inhibit dipeptidyl peptidase IV (DPPIV)
UAA200502704A UA78104C2 (en) 2002-08-29 2003-08-27 Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
BR0313831-3A BR0313831A (pt) 2002-08-29 2003-08-27 Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina
US10/525,748 US7304166B2 (en) 2002-08-29 2003-08-27 Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives
CA002496623A CA2496623C (en) 2002-08-29 2003-08-27 Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
MXPA05002253A MXPA05002253A (es) 2002-08-29 2003-08-27 Sales bencenosulfonato de derivados de 4-fluoro-2-cianopirrolidina.
JP2004532725A JP3746063B2 (ja) 2002-08-29 2003-08-27 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
HK06102523.6A HK1082497B (en) 2002-08-29 2003-08-27 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
EP03791325A EP1535907A4 (en) 2002-08-29 2003-08-27 BENZOLSULFONATE OF A 4-FLUORO-2-CYANOPYRROLIDINE DERIVATIVE
AU2003261748A AU2003261748B2 (en) 2002-08-29 2003-08-27 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
HR20050205A HRP20050205A2 (en) 2002-08-29 2003-08-27 Benzensulfonate of 4-fluoro-2-cyanopyrrolidine derivative
NO20050867A NO20050867L (no) 2002-08-29 2005-02-18 Benzensulfonat av 4-fluor-2-cyano-pyrrolidinderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002249821 2002-08-29
JP2002-249821 2002-08-29

Publications (1)

Publication Number Publication Date
WO2004020407A1 true WO2004020407A1 (ja) 2004-03-11

Family

ID=31972599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/010828 Ceased WO2004020407A1 (ja) 2002-08-29 2003-08-27 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩

Country Status (18)

Country Link
US (1) US7304166B2 (ja)
EP (1) EP1535907A4 (ja)
JP (1) JP3746063B2 (ja)
KR (1) KR100582141B1 (ja)
CN (1) CN1310885C (ja)
AU (1) AU2003261748B2 (ja)
BR (1) BR0313831A (ja)
CA (1) CA2496623C (ja)
EA (1) EA007613B1 (ja)
EC (1) ECSP055708A (ja)
HR (1) HRP20050205A2 (ja)
MX (1) MXPA05002253A (ja)
NO (1) NO20050867L (ja)
NZ (1) NZ538956A (ja)
PL (1) PL374664A1 (ja)
UA (1) UA78104C2 (ja)
WO (1) WO2004020407A1 (ja)
ZA (1) ZA200501418B (ja)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080401A1 (ja) 2005-01-27 2006-08-03 Mitsui Chemicals, Inc. フッ素化プロリン誘導体の製造方法
WO2006080412A3 (en) * 2005-01-28 2006-09-21 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2006100181A3 (en) * 2005-03-22 2006-11-30 Hoffmann La Roche New salt and polymorphs of a dpp-iv inhibitor
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038541A1 (en) * 2000-11-10 2002-05-16 Taisho Pharmaceutical Co., Ltd. Cyanopyrrolidine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP3107784B2 (ja) 1996-12-26 2000-11-13 宇部興産株式会社 光学活性ピペリジン誘導体の酸付加塩及びその製法
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
US6252063B1 (en) 1998-12-01 2001-06-26 Merck & Co., Inc. Crystalline salts of a carbapenem antibiotic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038541A1 (en) * 2000-11-10 2002-05-16 Taisho Pharmaceutical Co., Ltd. Cyanopyrrolidine derivatives

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2006080401A1 (ja) 2005-01-27 2006-08-03 Mitsui Chemicals, Inc. フッ素化プロリン誘導体の製造方法
WO2006080412A3 (en) * 2005-01-28 2006-09-21 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation
WO2006100181A3 (en) * 2005-03-22 2006-11-30 Hoffmann La Roche New salt and polymorphs of a dpp-iv inhibitor
US7772264B2 (en) 2005-03-22 2010-08-10 Hoffmann-La Roche Inc. Salt and polymorphs of a DPPIV inhibitor
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008120813A1 (ja) 2007-04-03 2008-10-09 Mitsubishi Tanabe Pharma Corporation ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
US8853385B2 (en) 2008-01-17 2014-10-07 Mitsubishi Tanabe Pharma Corporation Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
ZA200501418B (en) 2006-10-25
US20060106087A1 (en) 2006-05-18
EP1535907A1 (en) 2005-06-01
KR100582141B1 (ko) 2006-05-22
EP1535907A4 (en) 2006-11-29
NZ538956A (en) 2006-08-31
US7304166B2 (en) 2007-12-04
CA2496623A1 (en) 2004-03-11
HK1082497A1 (en) 2006-06-09
AU2003261748B2 (en) 2006-11-23
JPWO2004020407A1 (ja) 2005-12-15
UA78104C2 (en) 2007-02-15
BR0313831A (pt) 2005-07-05
NO20050867L (no) 2005-02-18
AU2003261748A1 (en) 2004-03-19
ECSP055708A (es) 2005-08-11
JP3746063B2 (ja) 2006-02-15
EA007613B1 (ru) 2006-12-29
EA200500420A1 (ru) 2005-08-25
PL374664A1 (en) 2005-10-31
CN1310885C (zh) 2007-04-18
CN1678575A (zh) 2005-10-05
KR20050059094A (ko) 2005-06-17
HRP20050205A2 (en) 2005-10-31
CA2496623C (en) 2008-02-12
MXPA05002253A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
JP3746063B2 (ja) ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
EP3560926B1 (en) 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors
JP2010513445A (ja) Ｇｌｋアクチベーターとして有用な新規結晶性化合物
CN111018891B (zh) 作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
ES3048491T3 (en) Ep2 antagonist
KR20120114174A (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
CA2826755A1 (en) Hybrid opioid compounds and compositions
WO2021236491A1 (en) Benzoylhydrazide-derived hdac degraders as therapeutics for treating cancer and other human diseases
CN106279121A (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
Prashanth et al. Cocrystal and coamorphous solid forms of enzalutamide with saccharin: Structural characterization and dissolution studies
WO2006043655A1 (ja) 吸入用医薬組成物
KR20210039417A (ko) 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법
KR20230159375A (ko) 의약에서 사용하기 위한 4-클로로-n-[2-[(4-클로로페닐)메틸]-3-옥소-1,2,4-티아디아졸-5-일]벤즈아미드
CA3113210A1 (en) Dp antagonist
JP2005272457A (ja) シアノピロリジン誘導体を有効成分として含有する医薬
US12630510B2 (en) EP2 antagonist
HK1082497B (en) Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
WO2025224102A1 (en) Hdac6 protacs and their use in the treatment of cancer, neurodegenerative diseases, inflammation and metabolic disorders
JP2025514066A (ja) 結晶形
HK40066780A (zh) 结晶形式
HK40067217A (zh) Ep2拮抗剂
TW202241398A (zh) 含有ｅｐ２拮抗劑之醫藥組成物
HK40035008B (zh) 杂环基氨基取代的三唑类化合物作为rho相关蛋白激酶的调节剂
JPH0640912A (ja) 発癌予防剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004532725

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200501418

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2496623

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 167089

Country of ref document: IL

Ref document number: 2003261748

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 374664

Country of ref document: PL

Ref document number: PA/a/2005/002253

Country of ref document: MX

Ref document number: 1020057003211

Country of ref document: KR

Ref document number: 1020057003191

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038203367

Country of ref document: CN

Ref document number: 1-2005-500403

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: P20050205A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2003791325

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 05024739

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 538956

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 463/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1200500369

Country of ref document: VN

Ref document number: 200500420

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2003791325

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057003211

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020057003191

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020057003191

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006106087

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10525748

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1020057003211

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10525748

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003791325

Country of ref document: EP